Pull to refresh
Logo
BioNTech mRNA cancer immunotherapy misses first goal in head and neck trial

BioNTech mRNA cancer immunotherapy misses first goal in head and neck trial

New Capabilities

BNT113 plus Keytruda failed to delay tumor progression; trial continues to test survival benefit

Today: AHEAD-MERIT trial misses PFS endpoint

Overview

Updated 54 minutes ago

BioNTech's experimental mRNA cancer treatment failed its first major test on Tuesday. The drug, BNT113, combined with Merck's Keytruda, did not delay tumor progression in patients with HPV16-positive head and neck cancer, missing the trial's first dual primary endpoint.

The trial continues to measure overall survival, and a statistically significant improvement there would still count as a positive outcome under the pre-specified design. But the miss is a setback for BioNTech's pivot to oncology, which became the company's focus after COVID vaccine sales collapsed.

Why it matters

BNT113's failure would undercut BioNTech's oncology pivot and the broader promise of mRNA cancer vaccines.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

6%
BioNTech share drop after PFS miss
Shares fell about 6% in early trading after the announcement.
Pending
Overall survival readout
The trial continues to evaluate OS, the second dual primary endpoint.
2
Dual primary endpoints in AHEAD-MERIT
PFS was missed; OS evaluation continues under the pre-specified statistical design.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2026 October 2026

3 events Latest: Today
  1. AHEAD-MERIT trial misses PFS endpoint

    Today Clinical Trial

    BNT113 plus pembrolizumab did not show statistically significant improvement in progression-free survival versus pembrolizumab alone. IDMC recommended continuing for OS evaluation.

  2. Analyst flags BNT113 evidence as sparse

    Analysis

    Leerink analyst Daina Graybosch wrote that evidence supporting BNT113's activity was sparse when the Phase 3 study launched.

  3. BioNTech reports colorectal cancer setback

    Clinical Trial

    The company reported a study setback in colorectal cancer earlier this year, adding to its oncology pipeline challenges.

Scenarios

1

BNT113 extends survival, trial declared positive

Possible Resolves by Q2 2028

Discussed by: BioNTech, BMO Capital Markets analysts

The IDMC recommended continuing the trial. If OS shows a statistically significant improvement, the trial is positive under the pre-specified design. Precedent exists: Keytruda itself missed PFS in an earlier head and neck cancer trial but improved OS. Türeci argued that immune-mediated antitumor effects can build and deepen over time, potentially showing durable benefits.

2

BNT113 fails to extend survival

Likely Resolves by Q2 2028

Discussed by: BMO Capital Markets analysts, Citi analyst Geoffrey Meacham

BMO analysts said the PFS miss made them 'significantly' less confident in OS. Many trials that miss PFS later fail OS. Meacham noted that head and neck cancer is heterogeneous and heavily immunosuppressed, making incremental efficacy over pembrolizumab challenging despite the HPV16 target.

3

OS shows trend without significance, BNT113 deprioritized

Possible Resolves by Q2 2028

Discussed by: Leerink Partners analyst Daina Graybosch

If OS shows a favorable trend without statistical significance, BioNTech may narrow development to a specific patient subgroup or shift resources to pumitamig, its bispecific cancer drug. Graybosch has said BioNTech is already leaning on pumitamig.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2016-2019

Keytruda in head and neck cancer (KEYNOTE-040, 2016)

Merck tested pembrolizumab (Keytruda) against standard chemotherapy in recurrent or metastatic head and neck cancer. The trial missed its progression-free survival endpoint but showed an overall survival benefit.

Then

Keytruda won approval for this indication based on the OS benefit.

Now

The drug became a standard first-line treatment for head and neck cancer, and the precedent showed that missing PFS does not doom a cancer drug.

Why this matters now

BioNTech is hoping BNT113 follows the same pattern: miss PFS but succeed on OS.

2013-2014

GSK MAGE-A3 cancer vaccine (2013-2014)

GSK's MAGE-A3 antigen-specific cancer immunotherapeutic failed Phase 3 trials in melanoma and non-small cell lung cancer, showing no benefit over placebo.

Then

GSK discontinued the program in 2014.

Now

It became a cautionary tale for therapeutic cancer vaccines, which have struggled to generate meaningful immune responses against established tumors.

Why this matters now

BNT113 uses mRNA technology rather than a protein antigen, but faces the same fundamental challenge: generating a durable immune response against an established tumor.

Sources

(11)